RANBP9 as potential therapeutic target in non-small cell lung cancer

Abstract

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the Western world. Despite progress made with targeted therapies and immune checkpoint inhibitors, the vast majority of patients have to undergo chemotherapy with platinum-based drugs. To increase efficacy and reduce potential side effects, a more comprehensive understanding of the mechanisms of the DNA damage response (DDR) is required. We have shown that overexpression of the scaffold protein RAN binding protein 9 (RANBP9) is pervasive in NSCLC. More importantly, patients with higher levels of RANBP9 exhibit a worse outcome from treatment with platinum-based drugs. Mechanistically, RANBP9 exists as a target and an enabler of the ataxia telangiectasia mutated (ATM) kinase signaling. Indeed, the depletion of RANBP9 in NSCLC cells abates ATM activation and its downstream targets such as p53 signaling. RANBP9 knockout cells are more sensitive than controls to the inhibition of the ataxia and telangiectasia-related (ATR) kinase but not to ATM inhibition. The absence of RANBP9 renders cells more sensitive to drugs inhibiting the Poly(ADP-ribose)-Polymerase (PARP) resulting in a “BRCAness-like” phenotype. In summary, as a result of increased sensitivity to DNA damaging drugs conferred by its ablation in vitro and in vivo, RANBP9 may be considered as a potential target for the treatment of NSCLC. This article aims to report the results from past and ongoing investigations focused on the role of RANBP9 in the response to DNA damage, particularly in the context of NSCLC. This review concludes with future directions and speculative remarks which will need to be addressed in the coming years.

Keywords

RANBP9 / RANBP10 / Scorpins / DNA damage / DNA repair / DNA damage response / CTLH complex / cisplatin / non-small cell lung cancer / PARP / BRCAness-like phenotype

References

[1] Siegel RL,Jemal A.Cancer statistics, 2019..CA Cancer J Clin2019;69:7-34

[2] Miller KD,Mariotto AB,Yabroff KR.Cancer treatment and survivorship statistics, 2019..CA Cancer J Clin2019;69:363-85

[3] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[4] Ettinger DS,Akerley W,Borghaei H.NCCN guidelines insights: non-small cell lung cancer, Version 4.2016..J Natl Compr Canc Netw2016;14:255-64

[5] Masters GA,Azzoli CG,Baker S Jr.Systemic therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update..J Clin Oncol2015;33:3488-515 PMCID:PMC5019421

[6] Herbst RS,Boshoff C.The biology and management of non-small cell lung cancer..Nature2018;553:446-54

[7] Jonna S.Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update..Discov Med2019;27:167-70

[8] Chan BA.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future..Transl Lung Cancer Res2015;4:36-54 PMCID:PMC4367711

[9] Giri A,Gajra A.Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer..Rev Recent Clin Trials2016;11:297-305

[10] Meng X,Zhang J,Xing L.PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges..Cancer Lett2017;405:29-37

[11] Ramamurthy C,Borghaei H.Immune checkpoint inhibitor therapy: what line of therapy and how to choose?.Curr Treat Options Oncol2017;18:33

[12] Darvin P,Sasidharan Nair V.Immune checkpoint inhibitors: recent progress and potential biomarkers..Exp Mol Med2018;50:165 PMCID:PMC6292890

[13] Carbone DP,Paz-Ares L,Horn L.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer..N Engl J Med2017;376:2415-26 PMCID:PMC6487310

[14] Santana-Davila R.The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer..Future Oncol2018;14:191-4

[15] Gettinger S,Chow LQ,Brahmer J.Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer..J Clin Oncol2016;34:2980-7 PMCID:PMC5569692

[16] Reck M,Robinson AG,Csoszi T.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer..N Engl J Med2016;375:1823-33

[17] Remon J,Soria JC.Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?.BMC Med2017;15:55 PMCID:PMC5346853

[18] Breimer LH,Olsson L.Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm..Scand J Clin Lab Invest2020;

[19] Hendriks LE,Besse B.Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy..Transl Lung Cancer Res2018;7:647-60 PMCID:PMC6249615

[20] Zarogoulidis P,Maragouli E,Sardeli C.Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 >/=50..Transl Lung Cancer Res2018;7:S28-30 PMCID:PMC5835639

[21] Paz-Ares L,Vicente D,Gumus M.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer..N Engl J Med2018;379:2040-51

[22] Gridelli C.The combination strategies will be ready the right first-line choice for squamous lung cancer patients?.Transl Lung Cancer Res2018;7:S349-51 PMCID:PMC6328703

[23] Passiglia F,Scagliotti GV.First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?.Transl Lung Cancer Res2019;8:546-9 PMCID:PMC6749125

[24] Gandhi L,Gadgeel S,Felip E.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer..N Engl J Med2018;378:2078-92

[25] Garon EB.Cancer immunotherapy trials not immune from imprecise selection of patients..N Engl J Med2017;376:2483-5

[26] Emens LA.The interplay of immunotherapy and chemotherapy: harnessing potential synergies..Cancer Immunol Res2015;3:436-43 PMCID:PMC5012642

[27] Salemi LM,Schild-Poulter C.Characterization of RanBPM molecular determinants that control its subcellular localization..PLoS One2015;10:e0117655 PMCID:PMC4319831

[28] Francis O,Adams JC.Molecular phylogeny of a RING E3 ubiquitin ligase, conserved in eukaryotic cells and dominated by homologous components, the muskelin/RanBPM/CTLH complex..PLoS One2013;8:e75217 PMCID:PMC3797097

[29] Tomastikova E,Kohoutova L,Vachova L.Interactions of an arabidopsis RanBPM homologue with LisH-CTLH domain proteins revealed high conservation of CTLH complexes in eukaryotes..BMC Plant Biol2012;12:83 PMCID:PMC3464593

[30] Salemi LM,McTavish CJ.Cell signalling pathway regulation by RanBPM: molecular insights and disease implications..Open Biol2017;7: PMCID:PMC5493780

[31] Lampert F,Goga A,Gilberto S.The multi-subunit GID/CTLH E3 ubiquitin ligase promotes cell proliferation and targets the transcription factor Hbp1 for degradation..Elife2018;7: PMCID:PMC6037477

[32] Maitland MER,Chiasson CA,Ma J.The mammalian CTLH complex is an E3 ubiquitin ligase that targets its subunit muskelin for degradation..Sci Rep2019;9:9864 PMCID:PMC6614414

[33] Qiao S,Chrustowicz J,Karayel O.Interconversion between anticipatory and active GID E3 ubiquitin ligase conformations via metabolically driven substrate receptor assembly..Mol Cell2019;

[34] Huffman N,Coppola V.The CTLH complex in cancer cell plasticity..J Oncol2019;2019:13 PMCID:PMC6907057

[35] Puverel S,Dolci S,Tessarollo L.RanBPM is essential for mouse spermatogenesis and oogenesis..Development2011;138:2511-21 PMCID:PMC3100708

[36] Palavicini JP,Hayes CD,Kang DE.RanBP9 plays a critical role in neonatal brain development in mice..PLoS One2013;8:e66908 PMCID:PMC3694151

[37] Palavicini JP,Bianchi E,Rao JS.RanBP9 aggravates synaptic damage in the mouse brain and is inversely correlated to spinophilin levels in Alzheimer’s brain synaptosomes..Cell Death Dis2013;4:e667 PMCID:PMC3698550

[38] Palavicini JP,Minond D,Xu S.RanBP9 overexpression down-regulates phospho-cofilin, causes early synaptic deficits and impaired learning, and accelerates accumulation of amyloid plaques in the mouse brain..J Alzheimers Dis2014;39:727-40

[39] Wang R,Wang H,Bianchi E.RanBP9 overexpression accelerates loss of dendritic spines in a mouse model of Alzheimer’s disease..Neurobiol Dis2014;69:169-79 PMCID:PMC4113832

[40] Atabakhsh E,Lefebvre KJ.RanBPM has proapoptotic activities that regulate cell death pathways in response to DNA damage..Mol Cancer Res2009;7:1962-72

[41] Liu T,Woo JA,Kang DE.Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis..Cell Death Dis2013;4:e476 PMCID:PMC3563991

[42] Kramer S,Miyazaki K,Hanamoto T.Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells..Oncogene2005;24:938-44

[43] Suresh B,Kim YS,Kim MS.Stability and function of mammalian lethal giant larvae-1 oncoprotein are regulated by the scaffolding protein RanBPM..J Biol Chem2010;285:35340-9 PMCID:PMC2975158

[44] Shao S,Satherley LK,Ji KE.Reduced RanBPM expression is associated with distant metastasis in gastric cancer and chemoresistance..Anticancer Res2016;36:1295-303

[45] Qin C,Wu G.RANBP9 suppresses tumor proliferation in colorectal cancer..Oncol Lett2019;17:4409-16 PMCID:PMC6447939

[46] Yin YX,Huang SH,Geng Z.RanBPM contributes to TrkB signaling and regulates brain-derived neurotrophic factor-induced neuronal morphogenesis and survival..J Neurochem2010;114:110-21

[47] Wang D,Schoen SR,Wu G.A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling..Biochem Biophys Res Commun2004;313:320-6

[48] Yuan Y,Chen H,Deng W.The Ran binding protein RanBPM interacts with TrkA receptor..Neurosci Lett2006;407:26-31

[49] Cheng L,Lemmon V.RanBPM is an L1-interacting protein that regulates L1-mediated mitogen-activated protein kinase activation..J Neurochem2005;94:1102-10 PMCID:PMC2424128

[50] Tessari A,Pawlikowski M,Rulli E.RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients..Oncogene2018; PMCID:PMC6690599

[51] Zhao Z,Zabkiewicz C,Zhang L.Reduced expression of RanBPM is associated with poorer survival from lung cancer and increased proliferation and invasion of lung cancer cells in vitro..Anticancer Res2017;37:4389-97

[52] Zhu LL,Yang HP.Expression of cartilage antitumor component RanBP9 in osteosarcoma..J Biol Regul Homeost Agents2016;30:103-10

[53] Liu H,Kohnlein K,Ori A.The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan..Autophagy2019;

[54] Bao J,Li J,Bhetwal BP.RAN-binding protein 9 is involved in alternative splicing and is critical for male germ cell development and male fertility..PLoS Genet2014;10:e1004825 PMCID:PMC4256260

[55] Matsuoka S,Smogorzewska A,Hurov KE.ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage..Science2007;316:1160-6

[56] Palmieri D,Tessari A,Amari F.Ran binding protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells..Oncotarget2016;7:18371-83 PMCID:PMC4951294

[57] DeWeirdt PC,Hanna RE,Sangree AK.Genetic screens in isogenic mammalian cell lines without single cell cloning..bioRxiv2019;

[58] Lord CJ.BRCAness revisited..Nat Rev Cancer2016;16:110-20

[59] Abbotts R,Biondi C,Goswami R.DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation..Proc Natl Acad Sci U S A2019;116:22609-18 PMCID:PMC6842607

[60] Pilie PG,Byers LA,Yap TA.PARP inhibitors: extending benefit beyond BRCA-mutant cancers..Clin Cancer Res2019;25:3759-71

[61] Liu Y,Aebersold R.On the dependency of cellular protein levels on mRNA abundance..Cell2016;165:535-50

[62] Vogel C.Insights into the regulation of protein abundance from proteomic and transcriptomic analyses..Nat Rev Genet2012;13:227-32 PMCID:PMC3654667

[63] Cui W,Bryson S,Ireland H.TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice..Cell1996;86:531-42

[64] Roberts AB.The two faces of transforming growth factor beta in carcinogenesis..Proc Natl Acad Sci U S A2003;100:8621-3 PMCID:PMC166359

[65] Lane DP.Cancer. p53, guardian of the genome..Nature1992;358:15-6

[66] Palmieri D,Coppola V.Scorpins in the DNA damage response..Int J Mol Sci2018;19: PMCID:PMC6032341

[67] Hosono K,Shimizu A,Ohtsubo M.YPEL5 protein of the YPEL gene family is involved in the cell cycle progression by interacting with two distinct proteins RanBPM and RanBP10..Genomics2010;96:102-11

[68] Denti S,Cheli A,Innamorati G.RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1..J Biol Chem2004;279:13027-34

[69] Coffill CR,Oh HK,Hogue KA.Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion..EMBO Rep2012;13:638-44 PMCID:PMC3388785

[70] Haupt Y,Kazaz A.Mdm2 promotes the rapid degradation of p53..Nature1997;387:296-9

[71] Domingues SC,Henriques AG,Fardilha M.RanBP9 modulates AICD localization and transcriptional activity via direct interaction with Tip60..J Alzheimers Dis2014;42:1415-33

[72] Ikura M,Fukuto A,Adachi J.Coordinated Regulation of TIP60 and Poly(ADP-Ribose) Polymerase 1 in damaged-chromatin dynamics..Mol Cell Biol2016;36:1595-607 PMCID:PMC4859686

[73] Ikura M,Matsuda S,Shima H.Acetylation of histone H2AX at Lys 5 by the TIP60 histone acetyltransferase complex is essential for the dynamic binding of NBS1 to damaged chromatin..Mol Cell Biol2015;35:4147-57 PMCID:PMC4648820

[74] Kaidi A.Retraction note: KAT5 tyrosine phosphorylation couples chromatin sensing to ATM signalling..Nature2019;568:576 PMCID:PMC6554193

[75] Legube G,Tyteca S,Scheffner M.Role of the histone acetyl transferase Tip60 in the p53 pathway..J Biol Chem2004;279:44825-33

[76] Tang Y,Zhang W.Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis..Mol Cell2006;24:827-39

[77] Wang Y,Li X,Debatin K.HIPK2 associates with RanBPM..Biochem Biophys Res Commun2002;297:148-53

[78] Hofmann TG,Bitomsky N.HIPK2: a tumour suppressor that controls DNA damage-induced cell fate and cytokinesis..Bioessays2013;35:55-64

[79] Winter M,Dauth I,Scheuermann K.Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR..Nat Cell Biol2008;10:812-24

[80] Meyer I,Schwiebert S,Italiano JE Jr.Altered microtubule equilibrium and impaired thrombus stability in mice lacking RanBP10..Blood2012;120:3594-602

[81] Beli P,Wagner SA,Olsen JV.Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response..Mol Cell2012;46:212-25 PMCID:PMC3565437

[82] Pines A,Vrouwe MG,Typas D.Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells..Mol Cell Biol2011;31:4964-77 PMCID:PMC3233030

[83] Elia AE,Wang DC,Everley RA.Quantitative Proteomic Atlas of Ubiquitination and Acetylation in the DNA Damage Response..Mol Cell2015;59:867-81 PMCID:PMC4560960

[84] Soliman SHA,Gardner ML,Breece CC.Tagging enhances histochemical and biochemical detection of ran binding protein 9 in vivo and reveals its interaction with Nucleolin..Sci Rep2020;10:7138 PMCID:PMC7188826

[85] Das S,Kim HH.RanBPM: a potential therapeutic target for modulating diverse physiological disorders..Drug Discov Today2017;

[86] Havugimana PC,Nepusz T,Turinsky AL.A census of human soluble protein complexes..Cell2012;150:1068-81 PMCID:PMC3477804

[87] Lisby M.Choreography of recombination proteins during the DNA damage response..DNA Repair (Amst)2009;8:1068-76 PMCID:PMC2729071

[88] Lisby M,Burgess RC.Choreography of the DNA damage response: spatiotemporal relationships among checkpoint and repair proteins..Cell2004;118:699-713

[89] Polo SE.Reshaping chromatin after DNA damage: the choreography of histone proteins..J Mol Biol2015;427:626-36 PMCID:PMC5111727

[90] Jacquet K,Avvakumov N,Roques C.The TIP60 complex regulates bivalent chromatin recognition by 53BP1 through direct H4K20me binding and H2AK15 acetylation..Mol Cell2016;62:409-21 PMCID:PMC4887106

[91] Mogi A.TP53 mutations in nonsmall cell lung cancer..J Biomed Biotechnol2011;2011:583929

[92] Simabuco FM,Pavan ICB,Silva FR.p53 and metabolism: from mechanism to therapeutics..Oncotarget2018;9:23780-823 PMCID:PMC5955117

[93] Liu J,Hu W.Tumor suppressor p53 and metabolism..J Mol Cell Biol2019;11:284-92 PMCID:PMC6487777

[94] Kim J,Chen W,Wu M.Wild-Type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation..Cancer Cell2019;35:191-203.e8